No influence of the polymorphisms <it>CYP2C19 </it>and <it>CYP2D6 </it>on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma
<p>Abstract</p> <p>Background</p> <p>The response to treatment varies among patients with multiple myeloma and markers for prediction of treatment outcome are highly needed. Bioactivation of cyclophosphamide and thalidomide, and biodegradation of bortezomib, is dependen...
Main Authors: | Vogel Ulla, Gregersen Henrik, Gimsing Peter, Abildgaard Niels, Andersen Niels F, Klausen Tobias W, Søeby Karen, Vangsted Annette J, Werge Thomas, Rasmussen Henrik B |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-08-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/10/404 |
Similar Items
-
Up-front fludarabine impairs stem cell harvest in multiple myeloma: report from an interim analysis of the NMSG 13/03 randomized placebo controlled phase II trial
by: Hans E. Johnsen, et al.
Published: (2009-08-01) -
Clinical Assessment of Bortezomib for Multiple Myeloma in Comparison with Thalidomide
by: Mitsutoshi Satoh, et al.
Published: (2011-02-01) -
Is the CYP2D6 Genotype Associated with Antipsychotic-Induced Weight Gain?
by: Gesche Jürgens, et al.
Published: (2022-10-01) -
In vitro and In silico studies of interactions of cathinone with human recombinant cytochrome P450 CYP(1A2), CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2E1, CYP2J2, and CYP3A5
by: Sharoen Yu Ming Lim, et al.
Published: (2022-01-01) -
Genetic variability of CYP2D6, CYP2B6, CYP2C9 and CYP2C19 genes across the Italian Peninsula
by: Francesco Carano, et al.
Published: (2018-01-01)